MEA BCG Vaccine Market

MEA BCG Vaccine Market Size 

The MEA BCG Vaccine Market is projected to grow from USD 2.62 billion in 2025 to USD 2.71 billion in 2026 and reach USD 3.54 billion by 2034, registering a CAGR of 3.41% from 2026 to 2034.

Increasing drug-resistant tuberculosis caseloads, increased investment in tuberculosis vaccine R&D, and rising tuberculosis prevalence are expected to fuel market revenue growth throughout the forecast period.

Increased demand for BCG vaccinations, owing to an increase in the number of newborn babies in the Middle East and Africa, will likely enhance market expansion in the future.

In the Middle East and Africa, the BCG vaccinations market is driven by rising tuberculosis prevalence and technological breakthroughs in vaccine development. Furthermore, increased government initiatives and a focus on immunization programs promote market growth.

Children who have tested negative for tuberculosis or are regularly exposed to untreated or ineffectively treated tuberculosis should consider getting the BCG vaccine. The BCG vaccine is particularly effective against severe tuberculosis in children, which has resulted in growing demand and is predicted to continue.

Increased tuberculosis prevalence, particularly in emerging and developing countries, as well as technological advancements in vaccine production, are driving the market for BCG vaccinations in the Middle East and Africa.

However, the market's expansion is stifled by unpleasant side effects and a scarcity of BCG vaccine. Furthermore, the need for BCG vaccinations is expected to grow due to unexplored market potential in emerging countries.

A decrease in the targeted tuberculosis incidence rate and a reduction in the targeted tuberculosis mortality rate is expected to impact the market significantly. However, BCG vaccination sales are expected to suffer due to the vaccine's low efficiency in adults.

However, side effects from the vaccine, such as a fever, headache, swollen glands, and discomfort at the injection site, may prevent some people from getting the BCG vaccine. In addition, a shortage of BCG vaccine supplies could also stymie market expansion.

This research report on the MEA BCG Vaccine Market has been segmented and sub-segmented into the following categories.

By Demographics:

• Pediatrics (0-18 years)
• Adults (19-35 years)            

By Product Type:

• BCG Vaccine Market
• Immune BCG
• Therapy BCG          

By End User:

• Pediatrics
• Adults       

By Applications:

• Home
• Commercial            

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Middle East and Africa BCG Vaccine Market accounted for a moderate share of the global BCG vaccine market due to the increased government programs and financing for TB vaccine acquisition and distribution, as well as a greater focus on pediatric TB immunization and the rising prevalence of drug-resistant tuberculosis in adults, are all contributing to the market's high revenue growth. In addition, the market expansion is likely to be fueled by the availability of modern healthcare infrastructure throughout the Middle East and Africa and favorable reimbursement regulations.

Immune BCG was responsible for the stable expansion of the Middle East and Africa's BCG vaccine market by pharmaceutical type. Pediatricians had the majority of the BCG vaccination market share in the UAE and Kuwait in 2021. In 2021, tuberculosis (TB) had the most significant market share. Hospitals and clinics dominate the BCG vaccine market, with hospitals accounting for the majority of sales.

The UAE BCG vaccine market is expected to proliferate due to increased vaccine procurement and availability in hospital settings and improved vaccination administration to neonates, which are predicted to boost hospital income over the projection period significantly.

The South African BCG vaccine market is predicted to grow significantly due to increased vaccination in the region due to increased government actions to purchase and distribute vaccines, favorable reimbursement rules, cutting-edge healthcare facilities, and greater immunization.

KEY MARKET PLAYERS

Leading companies dominating the MEA BCG Vaccine Market profiled in the report are Merck & Co., Inc., Serum Institute of India Pvt. Ltd., China National Biotec Group, InterVax Ltd., Sanofi Pasteur, Japan BCG Laboratory, GreenSignal Bio Pharma Limited (GSBPL), & Statens Serum Institute.,